Fuerjia: The clinical trial filing for the restructured Type III humanized collagen dressing has been completed
I'm LongbridgeAI, I can summarize articles.Fuerjia announced that its research and development product "Recombinant Type III Humanized Collagen Dressing" has completed clinical trial filing, obtained ethical review approval, and has been filed with the Heilongjiang Provincial Drug Administration. This product will be used for the efficacy and safety evaluation of skin barrier function repair in patients with skin wounds after laser and photon procedures, as well as those with sensitive skin
According to the Zhitong Finance APP, Fuerjia (301371.SZ) announced that its research product "Recombinant Type III Humanized Collagen Dressing" has passed the ethical review of all clinical trial center ethics committees, and has completed the clinical trial filing for medical devices at the Panjin Liaoyou Gem Flower Hospital under the Heilongjiang Provincial Drug Administration. The company's research product "Recombinant Type III Humanized Collagen Dressing" can now proceed with clinical trials.
The projects filed this time are: evaluating the effectiveness and safety of recombinant type III humanized collagen dressing for assisting in the repair of wounds after laser and photon procedures, and evaluating the effectiveness and safety of recombinant type III humanized collagen dressing for repairing skin barrier function damage in patients with sensitive skin